Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Raphael Pharmaceutical Inc. (RAPH)
Jaffa, IL
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +40.00% | +0.00% | +315.43% | -30.00% | -36.36% | -36.36% | -36.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+19.6% ★ Q1'26: +47.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +53.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.7% Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'26: 0.00× (vs Q1'25)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | Louria Hayon Igal | Officer | X-InTheMoney | A | Common Stock | 350,000 | 0.01 | 3.5K | 1,349,000 | D | ↗ |
| 2025-08-01 | Laor Zvi Laufer | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-10 | Eliya Yehuda | Director | A-Award | A | Warrant to purchase Common Stock | 200,000 | 1.00 | 200.0K | 200,000 | D | ↗ |
| 2025-03-05 | Dhadha Ajay Kumar | Director | A-Award | A | Common Stock | 350,000 | 0.00 | — | 351,667 | D | ↗ |
| 2025-03-02 | Pilo Shlomo | Director / Officer / 10% Owner | A-Award | A | Common Stock | 200,000 | 0.50 | 100.0K | 3,983,701 | D | ↗ |
| 2025-01-08 | Dhadha Ajay Kumar | Director | — | — | Common Stock | 0 | 0.00 | — | 403,153 | I | ↗ |
| 2023-11-25 | Eliya Yehuda | Director | A-Award | A | Common Stock | 150,000 | 0.40 | 60.0K | 352,000 | — | ↗ |
| 2023-08-29 | Louria Hayon Igal | Director / Officer | X-InTheMoney | A | Common Stock | 999,000 | 0.01 | 10.0K | 999,000 | — | ↗ |
| 2022-12-05 | Press Joseph | Director | A-Award | A | Warrants to Purchase Common Stock | 105,000 | 1.12 | 117.6K | 105,000 | — | ↗ |
| 2022-12-05 | Pilo Shlomo | Director / Officer / 10% Owner | A-Award | A | Warrants to Purchase Common Stock | 1,000,000 | 1.12 | 1.12M | 1,000,000 | — | ↗ |
| 2022-12-05 | Ofir Guy | Director / Officer | A-Award | A | Warrants to Purchase Common Stock | 1,000,000 | 1.00 | 1.00M | 1,000,000 | — | ↗ |
| 2022-12-05 | Louria Hayon Igal | Director / Officer | A-Award | A | Warrants to Purchase Common Stock | 999,000 | 0.01 | 10.0K | 990,000 | — | ↗ |
| 2022-12-05 | Eliya Yehuda | Director / Officer | A-Award | A | Warrants to Purchase Common Stock | 202,000 | 1.12 | 226.2K | 202,000 | — | ↗ |
| 2022-07-26 | Press Joseph | Director | A-Award | A | Common Stock | 280,000 | 0.00 | — | 280,000 | — | ↗ |
| 2022-07-26 | Ofir Guy | Director / Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,266,455 | — | ↗ |
| 2022-05-12 | Eliya Yehuda | Director | E-ExpireShort | D | Warrant to purchase Common Stock | 202,000 | 1.12 | 226.2K | 0 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Igal Louria Hayon | Chief Technology Officer | 288.0K | — |
| Shlomo Pilo | Chief Executive Officer & Director | 240.0K | male |
| Guy Ofir | General Counsel, Chief Financial Officer & Director | 144.0K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RAPH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
